Mossab Aljuaid
Salt Lake City, UTNPI 1245693480
Payments from drug & device makers
What this record shows
This record is dominated by grants: $37,500 of the $58,986 with a category attached, or 63.6%. 13 manufacturers reported payments, led by Abbott at 39.8% of the total. Reporting peaked in 2023 at $23,672 and has fallen 99.9% since, to $29 in 2025.
Across 183 payments — averaging $322.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Medtronic$18K
- Boston Scientific$16K
- Biotronik Inc.$872
- AstraZeneca$188
- Amgen$178
- plus $337 from 7 others
What the payments were for
- Grants$37,50064%
- Travel & lodging$12,15921%
- Food & beverage$8,08014%
- Education$1,2472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 74 | $23,450 |
| Medtronic(2 entities) | 50 | $17,851 |
| Boston Scientific | 26 | $16,111 |
| Biotronik Inc. | 9 | $872 |
| AstraZeneca | 6 | $188 |
| Amgen | 4 | $178 |
| Boehringer Ingelheim | 4 | $114 |
| Pfizer | 4 | $102 |
| Lantheus Medical Imaging, Inc. | 1 | $32 |
| Chiesi USA, Inc. | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$6,649
- ENSITE PRECISION$2,886
- ENSITE$1,957
- GENERAL - THERAPIES$1,146
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$779
- Micra$568
- AVEIR$287
- GALLANT$272
- QUADRA ASSURA$269
- S-ICD System Magnet$139
- Repatha$115
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $30,534 |
| Metoprolol Succinate | 20 | $394 |
| Omeprazole | 11 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $30,53437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Utahon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.